rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

LENSAR, Inc.

LNSR · Nasdaq

Health CareMedical DevicesNot moving yet

LNSR stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 8.4% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
76 (-10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders76-10 on the quarter
New · exited19 · 29
Reported value$25.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BRANDES INVESTMENT PARTNERS, LPadded · filed 14 Aug 20261,075,400$6.1M+50,224+4.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026402,806$2.3M+12,716+3.3%
Groupe la Francaiseunchanged · filed 25 Aug 2026213,537$1.2M00.0%
RBF Capital, LLCadded · filed 14 Aug 2026188,661$1.1M+143,134+314.4%
BlackRock, Inc.reduced · filed 7 Aug 2026185,033$1.1M-443,715−70.6%
CSS LLCunchanged · filed 14 Aug 2026163,450$933K00.0%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026151,609$866K-73,325−32.6%
CREDIT INDUSTRIEL ET COMMERCIALunchanged · filed 24 Jul 2026144,359$824K00.0%
Kerrisdale Advisers, LLCunchanged · filed 14 Aug 2026139,390$796K00.0%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026120,680$689K+108,115+860.4%
31 Mar 2023 – 30 Jun 2026
295784Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Aimee S. Weisner Company insiderDirector · last 3 Jun 20264 · 0
Alan B. Connaughton Company insiderChief Operating Officer · last 3 Jun 20260 · 0
Elizabeth G. O'Farrell Company insiderDirector · last 3 Jun 20260 · 0
Gary M. Winer Company insiderDirector · last 3 Jun 202622 · 0
Kendra Wong Company insiderPrincipal Accounting Officer · last 3 Jun 20260 · 0
Nicholas T. Curtis Company insiderChief Executive Officer · last 3 Jun 20260 · 0
Richard L. Lindstrom Company insiderDirector · last 3 Jun 20260 · 0
Thomas B. Ellis Company insiderDirector, 10% owner · last 3 Jun 20260 · 0
Todd B. Hammer Company insiderDirector, 10% owner · last 3 Jun 20260 · 0
William J. Link Company insiderDirector · last 3 Jun 20260 · 0
Thomas R. Staab II Company insiderChief Financial Officer · last 6 May 20262 · 0
John Peter McLaughlin Company insiderDirector · last 25 May 20230 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202546.4%
Operating profit marginFY 2025 · to 31 Dec 2025-42.1%
Free cash flow marginFY 2025 · to 31 Dec 2025-25.5%
Return on capital employedFY 2025 · to 31 Dec 2025-79.7%
Research spendFY 2025 · to 31 Dec 20259.6%
Share count trendFY 2025 · to 28 Feb 20260.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$13.0M
Free cash flowFY 2025 · to 31 Dec 2025−$14.9M

Analyst forecasts

No analyst forecasts yet.